The American Glaucoma Foundation grants award to the University of the Basque CountryNovember 09, 2004The prestigious American Glaucoma Foundation has recently awarded the research team of the Faculty of Medicine at the University of the Basque Country (EHU), led by cell biologist, Elena Vecino. This is the first time that the North American foundation has awarded a European research work. The project awarded by the American Glaucoma Foundation is entitled, "Study of neuroprotection of retinal ganglion cells in an experimental pig glaucoma model"; amongst the aims being to develop animal glaucoma models where the cellular and molecular mechanisms that cause the illness might be studied, to establish methodologies which enable prevention or at least early diagnosis, and to develop therapies that enable detaining the progress of the blindness caused by the pathology. The award is the financial subsidy of the research project which will be provided over two years and comes to 120,000 dollars. Glaucoma Glaucoma is one of the illnesses of the eye with the highest rate of incidence throughout the world, with more than two million new cases diagnosed annually. Family history, age and race are some of the "determining factors" in this ocular illness developing characterised, in a large percentage, by a sharp increase in intraocular pressure which, with time, causes the death of retinal cells to the point of irreversible blindness. The most serious problems confronted by the specialists in this field are that chronic glaucoma patients do not show clear symptoms until the illness is at an advanced stage and the fact that, at this point in time, it is not known what the factor are that trigger this cell death. Elena Vecina, the leader of an eight-strong research team in this project, has also recently been awarded first prize at the ONCE III International Awards Call in Biomedicine R+D and New Technologies for the Blind. Elhuyar Fundazioa |
|||||||||||||||||||||
| Related Glaucoma Current Events and Glaucoma News Articles 1930s drug slows tumor growth Drugs sometimes have beneficial side effects. A glaucoma treatment causes luscious eyelashes. A blood pressure drug also aids those with a rare genetic disease. Cataract surgery helps AMD patients; steroid improves DME; online eye health forum This month's Ophthalmology, the journal of the American Academy of Ophthalmology (Academy) reports on a national study that finds cataract surgery is likely to benefit patients with age-related macular degeneration (AMD) at all stages of the disease, on a clinical trial showing that the steroid triamcinolone may be effective in advanced diabetic macular edema (DME) patients when standard treatment fails, and on the public's use of two Academy-sponsored online eye health forums. Treating ROP in tiny preemies; better glaucoma follow-up in urban clinic Highlights of today's Scientific Program of the 2009 American Academy of Ophthalmology (AAO) - Pan-American Association of Ophthalmology (PAAO) Joint Meeting include: John T. Flynn, MD, Columbia University School of Medicine, discussing the ever-tougher challenges Eye M.D.s face in caring for the vision of the tiniest premature babies; and a report by Bradford W. Lee, MD, Stanford University School of Medicine, on barriers to glaucoma follow-up as perceived by patients in an urban, culturally diverse clinic. First in New York: Bionic technology aims to give sight to woman blinded beginning at age 13 A 50-year-old New York woman who was diagnosed with a progressive blinding disease at age 13 was implanted with an experimental electronic eye implant that has partially restored her vision. Toronto researchers discover novel circulation in human eye, new glaucoma treatment target Researchers at the University of Toronto, St. Michael's Hospital and Sunnybrook Health Sciences Centre have discovered a previously unidentified form of circulation within the human eye which may provide important new insights into glaucoma, a leading cause of blindness. Study predicts 40 percent increase in blindness in Nigeria by 2020 By 2020, 1.4 million Nigerians over age 40 will lose their sight, and the vast majority of the causes are either preventable or treatable, according to the Nigeria National Blindness and Visual Impairment Study Group. Unlikely genetic suspect implicated in common brain defect A genetic search that wound its way from patients to mouse models and back to patients has uncovered an unlikely gene critically involved in a common birth defect which causes mental retardation, motor delays and sometimes autism, providing a new mechanism and potentially improving treatment for the disorder. A drug-dispensing contact lens Taking eye drops multiple times a day can be difficult for patients to do, and because of blinking and tearing, as little as 1 to 7 percent of the dose is actually absorbed by the eye. Clue to normal-tension glaucoma; herpes infection and corneal transplants The July issue of Ophthalmology, the journal of the American Academy of Ophthalmology, includes two studies that may influence clinical treatment of serious eye conditions. Cell's split personality is a major discovery into neurological diseases Researchers at the Université de Montreal (UdeM) and the Montreal Neurological Institute (MNI), McGill University have discovered that cells which normally support nerve cell (neuron) survival also play an active and major role in the death of neurons in the eye. More Glaucoma Current Events and Glaucoma News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||